In patients with AF, we suggest prescription of oral anticoagulants could be considered as a result of an individualized clinical assessment taking into account overall AHRE burden (in the range of hours rather than minutes) and speci cally, the presence of AHRE > 24 h, individual stroke risk (using CHA2DS2- VASc), predicted risk bene t of oral anticoagulation and informed patient preferences (Ungraded consensus-based statement). Remark: In patients with CIED-detected AHRE, continued patient follow-up is recommended, preferentially combining clinical follow-up with remote monitoring of the CIED or else more frequent device interrogation than standard for CIED follow-up, to detect the development of clinical AF (symptomatic or asymptomatic), to monitor the evolution of AHRE or AF burden and speci cally the transition to AHRE lasting more than 24 h, onset or worsening of heart failure, or any clinical change that might suggest a change in clinical pro le or clinical conditions. 44. For patients with atrial utter, we suggest that antithrombotic therapy decisions follow the same risk-based recommendations as for AF (Ungraded consensus-based statement). 45. For women receiving OAC for prevention of stroke/TE in AF who become pregnant, we suggest discontinuation of OAC with a VKA between weeks 6 and 12 and replacement by LMWH twice daily (with dose adjustment according to weight and target anti- Xa level 4-6 h post-dose 0.8-1.2 U/mL), especially in patients with a warfarin dose required of > 5 mg/day (or phenprocoumon > 3 mg/day or acenocoumarol > 2 mg/day). OAC should then be discontinued and replaced by adjusted-dose LMWH (target anti-Xa level 4-6 h post-dose 0.8-1.2 U/mL) in the 36th week of gestation (Ungraded consensus-based statement). 46. 